Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | DAO | P14920 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13932148 | 0.92 | HPGD (0.61) | HPGDDAOMAPK1MEN1KMT2A | |
| SCHEMBL7821405 | 0.89 | HPGD (0.69) | HPGDDAOMAPK1MEN1KMT2A | |
| SCHEMBL7821453 | 0.82 | HPGD (0.64) | HPGDDAOMAPK1MEN1KMT2A | |
| SCHEMBL23934839 | 0.82 | HPGD (0.63) | HPGDDAOMAPK1MEN1KMT2A | |
| SCHEMBL3996660 | 0.78 | HPGD (1.00) | HPGDMAPK1 | |
| SCHEMBL1717207 | 0.75 | MEN1 (0.78) | HPGDDAOMEN1KMT2A | |
| SCHEMBL5115615 | 0.75 | HPGD (0.67) | HPGDDAOMAPK1MEN1KMT2A | |
| SCHEMBL24495513 | 0.75 | DAO (0.72) | HPGDDAOMAPK1MEN1KMT2A | |
| SCHEMBL4172709 | 0.75 | HPGD (0.67) | HPGDDAOMAPK1MEN1KMT2A | |
| SCHEMBL13384415 | 0.75 | HPGD (0.66) | HPGDDAOMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181199-B2 | Uracil derivatives and use thereof | RESPROTECT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181199-B2 | Uracil derivatives and use thereof | RESPROTECT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| WO-2009156182-A2 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2009-12-30 | — | — | WO | disclosed |
| EP-0748800-B1 | Pyrimidinedione, pyrimidinetrione, triazinedione derivatives as alpha-1-adrenergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2001-05-09 | — | — | EP | disclosed |
| US-5859014-A | USEFUL IN TREATMENT OF DISEASES INVOLVING DIRECTLY OR INDIRECTLY AN OBSTRUCTION OF THE LOWER URINARY TRACT, SUCH ASBENIGN PROSTATE HYPERPLASIA | SYNTEX (U.S.A.) INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0748800-A2 | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | TYMP, UNG, DPYD | HPGD 634/4885DAO 1976/4885MAPK1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.